

InspireMD, Inc.  
Form 8-K  
July 08, 2014

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

---

Date of Report (Date of earliest event reported): July 8, 2014

**InspireMD, Inc.**

(Exact name of registrant as specified in its charter)

|                                                   |                          |                                      |
|---------------------------------------------------|--------------------------|--------------------------------------|
| Delaware                                          | 001-35731                | 26-2123838                           |
| (State or other jurisdiction<br>of incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |

|                                          |            |
|------------------------------------------|------------|
| 321 Columbus Avenue                      | 02116      |
| Boston, Massachusetts                    |            |
| (Address of principal executive offices) | (Zip Code) |

Registrant's telephone number, including area code: (857) 453-6553

Edgar Filing: InspireMD, Inc. - Form 8-K

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

--Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

--Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

--Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

--Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On July 8, 2014, InspireMD, Inc. (the “Company”) issued a press release announcing that the Company concluded enrollment in its CGuard CARENET (carotid embolic protection study using micronet) clinical trial.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits.**

(d)Exhibits

| <b>Exhibit Number</b> | <b>Description</b> |
|-----------------------|--------------------|
|-----------------------|--------------------|

|      |                                  |
|------|----------------------------------|
| 99.1 | Press release dated July 8, 2014 |
|------|----------------------------------|

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**inspiremd, inc.**

Date: July 8, 2014 By: /s/ Craig Shore

Name: Craig Shore

Title: Chief Financial Officer

**EXHIBIT INDEX**

| <b>Exhibit Number</b> | <b>Description</b> |
|-----------------------|--------------------|
|-----------------------|--------------------|

|  |                                  |
|--|----------------------------------|
|  | Press release dated July 8, 2014 |
|--|----------------------------------|

|      |  |
|------|--|
| 99.1 |  |
|------|--|